159 completed. 159 Phase 1, 49 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 159 | Completed 159 |
| Phase 2 | 49 | Completed 49 |
Follow Neurodevelopmental Disorders: new trials by email Literature Review of Neurodevelopmental Disorders trials Research Report on Neurodevelopmental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Assess How Centanafadine Interacts With Stimulants in the Body Centanafadine, Methylphenidate, Lisdexamfetamine - ADHD | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 40 | 2026-02-05 | 2026-05-05 |
| A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder BI 3031185, Placebo - Borderline Personality Disorder, Attention Deficit Hyperactivity Disorder | Phase 1 | Completed | Boehringer Ingelheim | 78 | 2025-08-12 | 2026-08-10 |
| To Compare and Evaluate the Oral Bioavailability of Lisdexamfetamine 70 mg Capsule With That of Elvanse® 70 mg Capsules, Hard Lisdexamfetamine Dimesylate in Healthy, Adult, Human Subjects Under Fasting Conditions. Lisdexamfetamine capsule, Elvanse® (Lisdexamfetamine dimesylate capsules, hard) - Attention Deficit/Hyperactivity Disorder (ADHD) | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 48 | 2025-05-26 | 2025-08-01 |
| A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels CTN XR (TBM), CTN SR, CTN XR (Clin) - Attention Deficit Disorder With Hyperactivity | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 174 | 2024-08-29 | 2025-12-11 |
| Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD VCU-RRTC Online Course, Zoom Technical Assistance Sessions (6 total) - Intellectual Disability, Developmental Disability | Phase 1 | Completed | Virginia Commonwealth University | 60 | 2024-06-03 | 2025-07-31 |
| Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder Lumateperone 10.5 mg capsule, Lumateperone 21 mg capsule, Lumateperone 5 mg ODT - Autism Spectrum Disorder | Phase 1 | Completed | Intra-Cellular Therapies, Inc. | 33 | 2024-05-10 | 2026-07-24 |
| Impact VR: An Emotion Recognition and Regulation Training Program for Youth With CD Virtual Reality, Comparative Control - Conduct Disorder, Conduct Disorders in Children | Phase 1 | Completed | Virginia Commonwealth University | 220 | 2024-02-16 | 2026-06-17 |
| IAMA-6 Oral Dose Study in Healthy Adults IAMA-6, Placebo - Neurodevelopmental Disorders | Phase 1 | Completed | Iama Therapeutics S.r.l. | 72 | 2024-01-08 | 2026-02-20 |
| Use of MRI and cTBS for Catatonia in Autism Continuous Theta Burst in Transcranial Magnetic Stimulation - Autism Spectrum Disorder, Catatonia | Phase 1 | Completed | Vanderbilt University Medical Center | 26 | 2023-08-23 | 2025-12-31 |
| CTH120 First-in-Human Study: Single and Multiple Ascending Doses and Potential Food Interaction CTH120, Placebo - Fragile X Syndrome | Phase 1 | Completed | Connecta Therapeutics, S.L. | 76 | 2023-06-23 | 2025-01-23 |
| ASC - Autism Study Adipose tissue derived mesenchymal stromal/stem cells (Cell2Cure®) - Autism Spectrum Disorder, Gastrointestinal Dysfunction | Phase 1 | Completed | Cell to Cure ApS | 10 | 2023-06-09 | 2024-09-26 |
| Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects Centanafadine - Healthy Adult Participants | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 44 | 2023-03-08 | 2026-03-23 |
| Biomarkers of ADHD Treatment Response Concerta, Adderall-XR - ADHD | Phase 1 | Completed | Boston Children's Hospital | 16 | 2023-02-17 | 2024-12-18 |
| ADX-629 Therapy for Sjogren-Larsson Syndrome ADX-629 - Sjogren-Larsson Syndrome | Phase 1 / Phase 2 | Completed | University of Nebraska | 8 | 2023-01-02 | 2026-05-05 |
| Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities Nabilone - Intellectual Disability, Developmental Disability | Phase 1 | Completed | Hsiang-Yuan Lin | 20 | 2022-03-17 | 2026-01-23 |
| hCT-MSC Infusion in Adults With Autism Spectrum Disorder hCT-MSC - Autism Spectrum Disorder, Autism | Phase 1 | Completed | Joanne Kurtzberg, MD | 8 | 2022-01-24 | 2024-07-23 |
| 28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder SB-121, Placebo - Autistic Disorder | Phase 1 | Completed | Scioto Biosciences, Inc. | 15 | 2021-08-02 | 2024-03-25 |
| Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder. FEN164 - Autism Spectrum Disorder | Phase 1 / Phase 2 | Completed | Fenix Innovation Group | 18 | 2021-04-01 | 2026-09-08 |
| A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder Centanafadine - Attention-deficit Hyperactivity Disorder | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 50 | 2021-03-09 | 2023-07-13 |
| Open Label Phase I hCT-MSC in Toddlers With Autism Spectrum Disorder hCT-MSC infusion - Autism Spectrum Disorder | Phase 1 | Completed | Duke University | 12 | 2021-02-24 | 2025-02-24 |
Showing 20 of 159. Sign in to see all of them.
Attention Deficit Disorder with Hyperactivity (57) · Autistic Disorder (47) · Autism Spectrum Disorder (41) · Intellectual Disability (11) · Tourette Syndrome (9) · Child Development Disorders, Pervasive (6) · Asperger Syndrome (5) · Developmental Disabilities (5) · Fragile X Syndrome (5) · Learning Disabilities (5) · Anxiety Disorders (4) · Cerebral Palsy (4) · Mental Disorders (4) · Aggression (3)
Mental Disorders (155) · Child Development Disorders, Pervasive (67) · Attention Deficit and Disruptive Behavior Disorders (58) · Nervous System Diseases (41) · Autism Spectrum Disorder (32) · Neurologic Manifestations (26) · Pathological Conditions, Signs and Symptoms (25) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (24) · Signs and Symptoms (24) · Genetic Diseases, Inborn (22) · Neurobehavioral Manifestations (22) · Behavior (18) · Central Nervous System Diseases (17) · Brain Diseases (16)
Methylphenidate (8) · Lisdexamfetamine Dimesylate (6) · Oxytocin (5) · Cognitive Behavioral Therapy (4) · Dextroamphetamine (4) · 1-(naphthalen-2-yl)-3-azabicyclo(3.1.0)hexane (3) · Atomoxetine Hydrochloride (3) · Risperidone (3) · Capsules (2) · Hyperbaric Oxygenation (2) · Melatonin (2) · Probiotics (2) · Sodium Chloride (2) · Therapeutics (2) · Tobacco Use Cessation Devices (2)
Otsuka Pharmaceutical Development & Commercialization, Inc. (7) · Children's Hospital Medical Center, Cincinnati (6) · Hoffmann-La Roche (5) · Shire (4) · Yale University (4) · Boston Children's Hospital (3) · Duke University (3) · Aevi Genomic Medicine, LLC, a Cerecor company (2) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2) · Ironshore Pharmaceuticals and Development, Inc (2) · Joanne Kurtzberg, MD (2) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · Massachusetts General Hospital (2) · National Institute of Mental Health (NIMH) (2) · New York University (2)
United States (114) · United Kingdom (7) · Canada (6) · Germany (3) · Israel (3) · Japan (3) · Russia (3) · Brazil (2) · France (2) · India (2) · Norway (2) · Australia (1) · China (1) · Denmark (1) · Finland (1)
Joanne Kurtzberg, MD (4) · Jessica Sun, MD (3) · Craig Erickson, MD (2) · Geraldine Dawson, PhD (2) · Scott H Kollins, Ph.D. (2) · Aaron T Hogue, Ph.D. (1) · Aaron T Hogue, PhD (1) · Alan S Lewis, MD, PhD (1) · Alexander A Ostanin, MD, PhD (1) · Alexander Vinks, Pharm.D., Ph.D. (1) · Allen Song, PhD (1)
PMID 37811711, PMID 35690720, PMID 37120522, PMID 14605787, PMID 14662594, PMID 16554123, PMID 16930863, PMID 18625864, PMID 19948568, PMID 20145986, PMID 20680427, PMID 21356232, PMID 21883204, PMID 22537359, PMID 22588377, PMID 23106988, PMID 23978163, PMID 24297663, PMID 24439092, PMID 24472253, PMID 24664093, PMID 25313065, PMID 25526831, PMID 26336641, PMID 26547399, PMID 26631428, PMID 26913614, PMID 27711048, PMID 28122648, PMID 29039979, PMID 29339723, PMID 29792485, PMID 30153790, PMID 30196869, PMID 30230399, PMID 30967657, PMID 31763491, PMID 32082606, PMID 32242086, PMID 32616759, PMID 33087514, PMID 33473111, PMID 34034808, PMID 34232693, PMID 34303786, PMID 34693989, PMID 34826114, PMID 35377332, PMID 35594551, PMID 35607935
2019 (2), R01DC017476 (2), 2014 (1), K01MH079945 (1), K23MH081285 (1), K24DA023464 (1), R01AT010508 (1), R01DA011755 (1), R01DA033080 (1), R01DC010075 (1), R01HD095158 (1), R01MH052135 (1), R01MH063272 (1), R01MH073856 (1), R01NR010015 (1)